Page 8 - While Enzolytics Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(0) COLLEGE STATION, TX / ACCESSWIRE / April 5, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) (or the "Company"). In a significant development, recent findings have revealed that the monoclonal antibodies being produced by the Company against targeted sites on the Coronavirus are directed against epitopes that exist conservatively on each of the variant strains of the virus from the UK, Brazil and South African. These findings are considered by the Company as highly significant in that the Center for Disease Control (the "CDC") recently reported these Coronavirus as "variants of concern," defining ...

(0) COLLEGE STATION, TX / ACCESSWIRE / March 16, 2021 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company") today announced the formalization of corporate legal documents pursuant to Articles of Association forming International Medical Partners ("IMPL") a Bulgarian Limited Liability Company of which the Company is 50% owner. The agreements are with the Company's partners in IMBL formed with a group of successful Bulgarian businessmen. As a team, the Company with IMPL is moving forward to complete the initial production and certification of its ITV-1 patented therapeutics for treating HIV ...

Production of Monoclonal Antibodies Targeting These Sites Is in Process in the Company's Texas Lab COLLEGE STATION, TX / ACCESSWIRE / February 22, 2021 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company")

Press release content from Accesswire. The AP news staff was not involved in its creation. Enzolytics Announces the Discovery and Patenting of Eleven Newly Identified Conserved Target Sites on the SARS-CoV-2 Virus (Coronavirus) February 22, 2021 GMT Production of Monoclonal Antibodies Targeting These Sites Is in Process in the Company’s Texas Lab COLLEGE STATION, TX / ACCESSWIRE / February 22, 2021 / Enzolytics, Inc. (OTC Markets “ENZC” or the “Company”) today announced it has identified eleven conserved, expectedly immutable sites (epitopes) on the Coronavirus against which it is p...

(2) COLLEGE STATION, TX / ACCESSWIRE / February 16, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) (the "Company") announced today the results of an in vitro study of the Company's ITV-1/IPF peptide treatment that demonstrated the broad efficacy with low toxicity. The Company's ITV-1 peptide was tested against human corona virus 229E Strain (HCoV-229E) and exhibited comparable efficacy but with a 20-fold lower toxicity than the widely used anti-influenza medicine Tamiflu ®. Currently, the ITV-1/IPF therapeutic is being scheduled for further clinical trials to establish the breath of efficacy of th...